Los Angeles Capital Management
AKRO

Los Angeles Capital Management’s Akero Therapeutics AKRO Stock Holding History

Los Angeles Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,378
Closed -$303K – 2500
2025
Q3 		$303K Buy
6,378
+43
+0.7% +$2.08K ﹤0.01% 1125
2025
Q2 		$338K Sell
6,335
-1,155
-15% -$52.5K ﹤0.01% 1004
2025
Q1 		$303K Buy
+7,490
New +$317K ﹤0.01% 889
2024
Q2 		– Sell
-8,343
Closed -$211K – 1167
2024
Q1 		$211K Buy
+8,343
New +$200K ﹤0.01% 1097

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Los Angeles Capital Management's AKRO Position: Q4 2025 in Review

Los Angeles Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,378 shares — an estimated $303K sold.

Los Angeles Capital Management first reported a position in AKRO in Q1 2024 and held it in 4 quarters. The position peaked at $338K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Los Angeles Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 6,378 Akero Therapeutics shares in Q4 2025, an estimated $303K.
  • Los Angeles Capital Management first reported a position in Akero Therapeutics in Q1 2024 and held it in 4 quarters.
  • Los Angeles Capital Management's Akero Therapeutics position peaked at $338K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Los Angeles Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.